肾移植后血栓性微血管病
肾移植后血栓性微血管病(TMA)发生率为0.8%-15%,显著影响移植物和患者生存。本文综述其病理生理机制,涵盖补体介导、感染、自身免疫病及免疫抑制剂相关等类型,强调补体基因检测和抗补体治疗的重要性。
要点
- 肾移植后TMA发生率0.8%-15%,可表现为肾局限型或全身型。
- 复发性TMA几乎均为补体介导,需长期抗补体治疗。
- 补体基因检测对诊断和管理关键,早期识别和治疗可防移植物失败。
核心结论
- 肾移植后TMA是严重并发症,补体介导者需长期抗补体治疗且复发风险高,基因检测对诊断和管理至关重要。
研究设计与样本
- 综述,探讨肾移植后各类TMA的病理生理机制。
主要发现
- TMA发生于0.8%-15%的移植受者,特征为微血管病性溶血性贫血、血小板减少和小血管内皮损伤及微血栓形成。
- 复发性TMA几乎均为补体介导,而新发TMA与缺血再灌注损伤、免疫抑制剂、抗体介导排斥、病毒感染及自身免疫病复发等相关,补体过度激活也可能参与。
- 非补体基因相关TMA常为更广泛综合征的一部分,具有独特临床特征。
关键数值与推荐
- 复发性TMA几乎均为补体介导,对支持治疗无反应,需长期抗补体治疗,复发风险高。
- 补体基因检测是正确诊断和管理的关键。
- 对与其它疾病相关的TMA亚群,补体激活可能参与,及时启动抗补体治疗同样重要。
临床怎么用
- 肾移植后怀疑TMA应尽早识别,区分补体介导与其他原因,以指导抗补体治疗决策。
- 对复发性TMA或疑似补体介导者,应进行补体基因检测。
- 早期治疗以防移植物失败和其他严重并发症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Thrombotic microangiopathy (TMA) is a challenging and serious complication of kidney transplantation that significantly affects graft and patient survival, occurring in 0.8%-15% of transplant recipients. TMA is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ injury due to endothelial damage and microthrombi formation in small vessels. However, clinical features can range from a renal-limited form, diagnosed only on a kidney biopsy, to full-blown systemic manifestations, which include neurologic, gastrointestinal, and cardiovascular injury. TMA can arise because of genetic or acquired defects such as in complement-mediated TMA or can occur in the context of other conditions like infections, autoimmune diseases, or immunosuppressive drugs, where complement activation may also play a role. Recurrent TMA after kidney transplant is almost always complement-mediated, although complement overactivation may also play a role in de novo post-transplant TMAs associated with ischemia-reperfusion injury, immunosuppressive drugs, antibody-mediated rejection, viral infections, and relapse of autoimmune diseases, such as antiphospholipid antibody syndrome. Differentiating between a complement-mediated process and one triggered by other factors is often challenging but critical to minimize allograft damage because the former is nonresponsive to supportive therapy, needs long-term anticomplement therapy, and has a high risk of recurrence. Given the central role of complement and effect of genetic defects on the risk of recurrence in many forms of post-transplant TMA, genetic testing for complement disorders is key for proper diagnosis and management. Given that complement activation may also play a role in a subset of TMAs associated with other conditions, prompt recognition and timely initiation of anticomplement therapy is equally important. In addition, TMA associated with noncomplement genes, often part of a broader syndromic process with distinct clinical features, has also been described. Early identification and treatment are essential to prevent graft failure and other severe complications. This review explores the pathophysiologic mechanisms underlying various post-transplant TMAs.
引用
- Java A, Sparks MA, Kavanagh D, et al. Post-transplant Thrombotic Microangiopathy. J Am Soc Nephrol. 2025. PMID: 39888686. doi:10.1681/ASN.0000000645
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。